Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 3
2014 1
2016 2
2017 2
2019 1
2020 1
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R. Röth A, et al. Among authors: sostelly a. Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399. Blood. 2020. PMID: 31978221 Free PMC article. Clinical Trial.
Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.
Nishimura JI, Soubret A, Arase N, Buatois S, Hotta M, Charoin JE, Ito Y, Sreckovic S, Takamori H, Bucher C, Ueda Y, Hernández-Sánchez J, Gotanda K, Jordan G, Shinomiya K, Ramos J, Kim JS, Panse J, de Latour RP, Röth A, Morii E, Schrezenmeier H, Isaka Y, Sica S, Kanakura Y, Yoon SS, Kinoshita T, Paz-Priel I, Sostelly A. Nishimura JI, et al. Among authors: sostelly a. Clin Pharmacol Ther. 2023 Apr;113(4):904-915. doi: 10.1002/cpt.2851. Epub 2023 Feb 12. Clin Pharmacol Ther. 2023. PMID: 36660902
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
Röth A, Ichikawa S, Ito Y, Kim JS, Nagy Z, Obara N, Panse J, Schrezenmeier H, Sica S, Soret J, Usuki K, Yoon SS, Balachandran N, Buri M, Lundberg P, Patel H, Shinomiya K, Sostelly A, Nishimura JI. Röth A, et al. Among authors: sostelly a. Eur J Haematol. 2023 Aug;111(2):300-310. doi: 10.1111/ejh.14011. Epub 2023 Jun 15. Eur J Haematol. 2023. PMID: 37321625 Clinical Trial.
Tumor Static Concentration Curves in Combination Therapy.
Cardilin T, Almquist J, Jirstrand M, Sostelly A, Amendt C, El Bawab S, Gabrielsson J. Cardilin T, et al. Among authors: sostelly a. AAPS J. 2017 Mar;19(2):456-467. doi: 10.1208/s12248-016-9991-1. Epub 2016 Sep 28. AAPS J. 2017. PMID: 27681102
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
Chatterjee MS, Elassaiss-Schaap J, Lindauer A, Turner DC, Sostelly A, Freshwater T, Mayawala K, Ahamadi M, Stone JA, de Greef R, Kondic AG, de Alwis DP. Chatterjee MS, et al. Among authors: sostelly a. CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):29-39. doi: 10.1002/psp4.12140. Epub 2016 Nov 29. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 27896938 Free PMC article.
Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.
Nishimura JI, Usuki K, Ramos J, Ichikawa S, Buri M, Kiialainen A, Sostelly A, Peffault de Latour R, Paz-Priel I, Röth A. Nishimura JI, et al. Among authors: sostelly a. Br J Haematol. 2022 Aug;198(3):e46-e50. doi: 10.1111/bjh.18274. Epub 2022 May 24. Br J Haematol. 2022. PMID: 35608260 No abstract available.
12 results